Answers are grounded in this paper and cite their sources.
BACKGROUND: Lateral lymph node metastasis (LLNM) is a significant risk factor for poor prognosis in papillary thyroid carcinoma (PTC). Data on the association between LLNM and genetic alterations in PTC remains limited. This study investigated clinicopathological and molecular predictive factors for LLNM in patients with PTC. METHODS: and telomerase reverse transcriptase (TERT) promoter mutations, were assessed to identify predictors of LLNM. The impact of these features on disease-free survival (DFS) was analyzed using multivariable Cox regression. RESULTS: LLNM was found in 154 (25.5 %) patients. Independent predictors of LLNM included age < 55 years (odds ratio [OR] = 2.491, 95 % confidence interval [CI]: 1.411-4.398), multifocality (OR = 2.056, 95 % CI: 1.254-3.370), lymphatic invasion (OR = 1.811, 95 % CI: 1.094-2.997), gross extrathyroidal extension (ETE) (OR = 2.611, 95 % CI: 1.333-5.115), central lymph node metastasis (CLNM) without extranodal extension (ENE) (OR = 12.060, 95 % CI: 4.205-34.595) or with ENE (OR = 68.060, 95 % CI: 23.224-199.453), and TERT promoter mutation (OR = 2.272, 95 % CI: 1.078-4.786). CLNM with ENE, LLNM with ENE and TERT promoter mutation were significantly correlated with shorter DFS. CONCLUSIONS: LLNM is not rare in PTC and represents an adverse prognostic factor significantly associated with age, gross ETE, multifocality, lymphatic invasion, CLNM, and TERT promoter mutation.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: